These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 15563356)
21. A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model. Mussen F; Salek S; Walker S; Phillips L Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S16-41. PubMed ID: 17546574 [TBL] [Abstract][Full Text] [Related]
22. Trading on traditional medicines. Basu P Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941 [No Abstract] [Full Text] [Related]
23. Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials. Howard G; McClure LA; Krakauer JW; Coffey CS Curr Opin Neurol; 2007 Feb; 20(1):71-7. PubMed ID: 17215692 [TBL] [Abstract][Full Text] [Related]
26. Ticlopidine: a second look. No further use in routine practice. Prescrire Int; 1999 Oct; 8(43):142-4. PubMed ID: 11503839 [TBL] [Abstract][Full Text] [Related]
27. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Paczynski RP; Alexander GC; Chinchilli VM; Kruszewski SP Int J Risk Saf Med; 2012 Jan; 24(3):137-46. PubMed ID: 22936056 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. Panicker GK; Karnad DR; Salvi V; Kothari S J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547 [TBL] [Abstract][Full Text] [Related]
29. [Problems in evaluating new antipsychotic drugs]. Fleischhacker WW Wien Med Wochenschr; 1998; 148(11-12):266-72. PubMed ID: 9746969 [TBL] [Abstract][Full Text] [Related]
30. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention. Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182 [No Abstract] [Full Text] [Related]
31. Regulators should better leverage effectiveness standards to enhance drug value. Naci H; Alexander GC Pharmacotherapy; 2014 Oct; 34(10):1005-11. PubMed ID: 25041851 [TBL] [Abstract][Full Text] [Related]
32. Many clinical studies may not be dependable. Adams KT Manag Care; 2014 Oct; 23(10):36-7. PubMed ID: 25942784 [No Abstract] [Full Text] [Related]
33. [Introduction to Good Manufacturing Practice for investigational agents]. Sakakibara T Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):170-3. PubMed ID: 22498682 [No Abstract] [Full Text] [Related]
34. A revolution in drug approval practices is required. Mander A BMJ; 2012 Nov; 345():e8002. PubMed ID: 23183068 [No Abstract] [Full Text] [Related]
35. The drug annotations series. Zablocki J; Garcia-Echeverria C J Med Chem; 2013 Sep; 56(17):6541. PubMed ID: 24000804 [No Abstract] [Full Text] [Related]
36. John Bell's conflict of interest. Baylis MR BMJ; 2012 Nov; 345():e7701. PubMed ID: 23150223 [No Abstract] [Full Text] [Related]